Akouos to Present at BTIG Virtual Biotechnology Conference

Aug 3, 2020

BOSTON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for people worldwide who live with disabling hearing loss, today announced that Manny Simons, Ph.D., M.B.A., CEO, President and co-founder, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10 at 10:30 a.m. ET.

A live webcast of the fireside chat will be accessible through the investors section of the company’s website at www.akouos.com. To access the webcast, please go on to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Akouos’ website for 14 days following the conference.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for people worldwide who live with disabling hearing loss. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

 

 

Akouos Logo.png

 

Source: Akouos, Inc.